BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20523105)

  • 1. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
    Lee CK; Choi JS
    Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
    Li X; Choi JS
    Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
    Choi BC; Choi JS; Han HK
    Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
    Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
    Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
    Li C; Lee MY; Choi JS
    Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cysteine on the pharmacokinetics of paclitaxel in rats.
    Lee YK; Han SY; Chin YW; Choi YH
    Arch Pharm Res; 2012 Mar; 35(3):509-16. PubMed ID: 22477198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
    Jin J; Bi H; Hu J; Zhong G; Zhao L; Huang Z; Huang M
    Biopharm Drug Dispos; 2010 May; 31(4):264-8. PubMed ID: 20437465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
    Varma MV; Panchagnula R
    Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
    Li X; Choi JS
    Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
    Li C; Li X; Choi JS
    Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of morin on the pharmacokinetics of etoposide in rats.
    Li X; Yun JK; Choi JS
    Biopharm Drug Dispos; 2007 Apr; 28(3):151-6. PubMed ID: 17315145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.
    Li C; Kim M; Choi JS
    Arch Pharm Res; 2010 Sep; 33(9):1395-400. PubMed ID: 20945138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
    Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
    Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
    Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
    Lee K; Chae SW; Xia Y; Kim NH; Kim HJ; Rhie S; Lee HJ
    Eur J Pharmacol; 2014 Jan; 723():381-8. PubMed ID: 24252806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
    Torne SJ; Ansari KA; Vavia PR; Trotta F; Cavalli R
    Drug Deliv; 2010 Aug; 17(6):419-25. PubMed ID: 20429848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.